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Abstract 
Background High potency statin therapy is recommended in the secondary prevention of 
cardiovascular disease but discontinuation, dose reduction, statin switching and/or non-
adherence occur in practice.   
Objectives To determine the prevalence and predictors of deviation from high potency 
statin use early after a non-ST elevation acute coronary syndrome (NSTE-ACS), and its 
association with subsequent major adverse cardiovascular events (MACE) and all-cause 
mortality (ACM).   
Methods 1,005 patients from a UK-based prospective NSTE-ACS cohort study discharged 
on high potency statin therapy (atorvastatin 80mg, rosuvastatin 20mg or 40mg daily) were 
included.  At one month, patients were divided into constant high potency statin users, and 
suboptimal users incorporating statin discontinuation, dose reduction, switching statin to a 
lower equivalent potency and/or statin non-adherence.  Follow up was a median 16 months. 
Results There were 156 suboptimal (~15.5%) and 849 constant statin users.  Factors 
associated in multivariable analysis with suboptimal statin occurrence included female sex 
(odds ratio (OR) 1.75, 95% confidence interval (CI) 1.14-2.68) and muscular symptoms (OR 
4.28, 95% CI 1.30-14.08).  Suboptimal statin use was associated with increased adjusted 
risks of time to MACE (hazard ratio (HR) 2.10, 95% CI 1.25-3.53, p=0.005) and ACM (HR 
2.46, 95% CI 1.38-4.39, p=0.003).  Subgroup analysis confirmed that the increased 
MACE/ACM risks were principally attributable to statin discontinuation/non-adherence. 
Conclusion Conversion to suboptimal statin use is common early after NSTE-ACS, and is 
partly related to muscular symptoms.  Statin discontinuation/non-adherence carries an 
adverse prognosis.  Interventions that preserve and enhance statin utilisation could improve 
post NSTE-ACS outcomes.  
 
Key words 
Statin, cardiovascular, mortality, discontinuation, non-adherence, muscular symptoms 
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Introduction 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide1, 2. In the US and 
the UK, CVD accounts for the largest and second largest proportions of healthcare 
expenditure of any disease category, respectively3-5.  Although an acute coronary syndrome 
(ACS) is a sudden event, most of the morbidity and mortality accrues later, following 
hospital discharge.  Statins are 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) 
reductase inhibitors that reduce circulating low-density lipoprotein-cholesterol (LDL-C).  
Following an ACS, high potency statin therapy, prescribed as atorvastatin 80mg daily, is 
indicated because it has been demonstrated in randomized controlled trials (RCTs) to be 
highly effective and superior to both placebo and moderate statin therapy for reducing 
cardiovascular events6-8.  However, the effectiveness of drugs in RCTs can be undermined in 
clinical practice by several factors including poor adherence, discontinuation, and switching 
prescriptions to a lower equivalent potency.  Poor statin adherence has been reported in up 
to 50% of patients9, statin discontinuation rates vary from 15%10 to 60-75%11, 12 and 
changing to lower potency statin therapy has been noted in ~1%13 to 42%14 of patients.   
 
It is important to understand the clinical consequences of deviating from recommended high 
potency statin therapy in high-risk patients who have had at least one cardiovascular event.  
The adverse effects of statin non-adherence and discontinuation on cardiovascular clinical 
outcomes have been investigated previously15-17, but relatively little is known about the 
impact of statin dose reductions and/or switching to a statin of lower equivalent potency in 
real world secondary prevention14.  The collective extent to which statin discontinuation, 
dose reduction, switching and/or non-adherence occur early in secondary prevention is also 
under-reported.  Furthermore, few real world statin adherence studies have focussed 
exclusively on non-ST elevation ACS (NSTE-ACS) patients, which as a group are often 
older, have more comorbidities, are more likely to receive non-interventional medical 
management and have a worse long term prognosis than patients suffering an ST-elevation 
myocardial infarction (STEMI)18-20 and so may be more susceptible to insufficient statin 
therapy.  
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Therefore, the aims of this study were to investigate: i) the prevalence of, ii) the risk factors 
for, and iii) the clinical consequences associated with conversion from high potency to 
‘suboptimal’ statin use due to statin discontinuation, dose reduction, switching to an 
alternative statin of lower equivalent potency and/or statin non-adherence, early after an 
NSTE-ACS in a contemporary prospective cardiovascular cohort.   
 
Material and methods 
Prospective study outline 
This investigation utilises a prospective CVD observational study that was conducted at 16 
different UK hospital sites between 2008-2013, entitled the Pharmacogenetics of Acute 
Coronary Syndrome (PhACS).  1470 patients hospitalised with an NSTE-ACS (both non-ST 
elevation myocardial infarction (NSTEMI) and unstable angina) were eligible for inclusion 
in PhACS.  Patients were followed up at one (visit 2 (V2)) and 12 months (visit 3 (V3)) post 
recruitment, and annually thereafter until all participants had been followed up for at least 12 
months.  Further study information is provided in the Supplement.   
 
The protocol was approved by the Liverpool (adult) research Ethics Committee, UK; site-
specific approval was granted at all sites involved and local informed consent was obtained 
from all study subjects in accordance with the Declaration of Helsinki.   
 
Cohort Selection 
Patients were eligible for inclusion in the current study if they were discharged on a high 
potency statin from their index hospital NSTE-ACS admission.  High potency statin therapy 
was: atorvastatin 80mg daily, the equivalently potent rosuvastatin 20mg, and rosuvastatin 
40mg daily (see eTable 1 in the Supplement for relative potency information).  All other 
statins and doses were considered non-high potency statin therapy.  Patients were excluded 
if they died within 30 days of discharge, because this prevented assessment of suboptimal 
statin status during follow up (see below).  Patients were excluded if their V2 occurred 
during a prolonged index hospital admission or did not actually occur until >180 days after 
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index admission (as ~85% of muscular symptoms occur within 180 days21), or they were 
lost to follow up following V2.   
 
Assessment of statin adherence 
At V2, cardiac medication adherence was assessed using the Brief Medication Questionnaire 
(BMQ) (eFigure 1 in the Supplement)22.  The BMQ incorporates three screens: a regimen 
screen, belief screen and a recall screen.  The BMQ has been compared to the Medication 
Events Monitoring System.22  The regimen screen had a sensitivity of 80% for detecting 
repetitive non-adherence and did not classify any adherent patients as non-adherent.  
However, it had 0% sensitivity for detecting sporadic non-adherence, and so its overall 
accuracy was 95%22.  Further information about the BMQ is available in the Supplement.  
For the main analysis, assessment of adherence utilised the regimen screen; patients were 
classed statin non-adherent if they reported missing at least one statin pill over the past 
week.   
 
Classification of suboptimal statin use 
Patients were designated ‘suboptimal statin users’ if, by V2, they had discontinued, reduced 
their statin dose, switched to an alternative statin of lower equivalent potency and/or were 
statin non-adherent.  Patients that were on high potency statin therapy at baseline and V2 
and were statin adherent represented ‘constant statin users’.   
 
Outcomes 
i) Suboptimal statin use at V2 was itself the outcome for investigating clinical 
factors associated with its occurrence. 
ii) For investigating potential sequelae of suboptimal statin use, the primary 
endpoint was time to first major adverse cardiovascular event (MACE): a 
composite of death from a CVD (or no known) cause, or non-fatal myocardial 
infarction or ischaemic stroke.  Time to all-cause mortality (ACM) was the 
secondary endpoint. 
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Covariates  
The following were considered for investigating factors associated with suboptimal statin 
occurrence: age≥75, sex, body mass index (BMI)≥30, hypertension, hyperlipidaemia, 
diabetes mellitus, smoking (current or previous versus non-smokers), chronic kidney 
disease, chronic obstructive pulmonary disease (COPD), prior CVD (previous MI, stroke, 
transient ischaemic attack (TIA) or peripheral artery disease (PAD)), statin use prior to 
index admission, raised index troponin, high potency statin discharged on 
(atorvastatin/rosuvastatin), treatment with PCI or CABG surgery during or within 30 days 
following discharge from index admission, New York Heart Association (NYHA) functional 
class at V2, reported use at V2 of aspirin, a P2Y12 inhibitor, a beta blocker, an angiotensin 
converting enzyme inhibitor or angiotensin II receptor blocker (ACEI/ARB), warfarin, or a 
proton pump inhibitor (PPI), concomitant use of levothyroxine (a surrogate for 
hypothyroidism) or a drug(s) that inhibits cytochrome P450 3A4 (CYP3A4) (listed in the 
Supplement), and muscular symptoms recorded at V2 (bothersome muscular 
pains/cramps/aches/weakness whilst on statin therapy recorded in the BMQ).   
 
For the analyses investigating the risks of MACE and ACM, all of the above covariates were 
included except muscular symptoms, levothyroxine, CYP3A4-inhibiting drugs, and type of 
high potency statin discharged on.  Follow up commenced from the date of V2.  
 
Subgroup analyses 
Suboptimal statin use was divided into those who had discontinued or were statin non-
adherent, and those who had reduced statin dose or switched statin (but were statin 
adherent), and the risks of time to MACE and ACM were analysed for both subgroups, 
compared to constant statin users. 
 
Statistical analysis 
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Overall, 4.3% of data were missing, but 28.6% of cases had at least one missing value.  This 
missing data were handled as follows.  First, missing V2 dates were imputed by adding 30 
days to baseline discharge date, because 30 days represented the median duration of the non-
missing data.  Second, V2 drug data were manually imputed where possible by comparison 
of baseline and V3 drug data.  Missing V2 muscular symptoms were also manually imputed 
as ‘no symptoms’, because only 1.2% of patients openly reported symptoms.  Lastly, 
multiple imputation was used:  all remaining missing values were sampled using a fully 
conditional specification method, which uses an iterative Markov chain Monte Carlo 
procedure, and ten imputation datasets were generated.  See the Supplement for further 
details.   
i) Investigating factors associated with suboptimal statin use 
Following imputation, the null hypothesis of no association with suboptimal statin 
occurrence (compared to constant statin use) was tested for each variable using the Wald 
test, because it generates a pooled value from the ten datasets.  Those covariates with 
univariate p<0.1 were entered into a multivariable logistic regression model, using forwards 
stepwise (likelihood ratio) selection.  Odds ratios (OR) and p-values are pooled from the ten 
imputed datasets; p<0.05 indicated significance.  
ii)  Investigating risks of MACE and ACM associated with suboptimal statin 
use 
A univariate Cox proportional hazard model was fitted for each covariate to test its 
association with time to MACE; the same was performed for time to ACM.  For each 
covariate, the Cox proportional hazards assumption was assessed by visual inspection of 
Kaplan-Meier curves.  If a covariate did not meet the proportional hazards assumption, it 
was excluded from the main analyses (see sensitivity analyses D1 and D2).  Covariates 
meeting the proportional hazards assumption and p-value<0.1 in univariate analysis were 
taken forwards into multivariable Cox proportional hazards modelling, with the final 
multivariable model covariates chosen by forwards stepwise (likelihood ratio) selection.  
After the covariate model had been fitted for both time to MACE and time to ACM, 
suboptimal statin use was introduced into both models to test its adjusted association with 
risk of MACE, or ACM.  The hazard ratios (HR) and p-values provided in the results section 
are pooled results across all imputed datasets, except in the complete cases sensitivity 
analyses.   
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As two outcomes (MACE, ACM) were investigated here, a Bonferroni correction was used 
to adjust the significance threshold to p≤0.025.  This threshold was also applied to all 
sensitivity analyses that further examined the risks of MACE or ACM associated with 
suboptimal statin use (see below). 
 
Sensitivity Analyses 
To investigate result robustness, sensitivity analyses were undertaken (see the Supplement 
for details). Firstly, a subcohort consisting of all cases with complete data (‘complete cases’) 
assessed whether missing data impacted either the factors associated with suboptimal statin 
occurrence or the associations between suboptimal statin use and risk of MACE/ACM.  
Additional sensitivity analyses evaluated the robustness of the associations between 
suboptimal statin use and MACE/ACM further by: expanding the statin non-adherence 
definition, considering covariates that did not meet the proportional hazards assumption for 
full follow up duration, including all variables that differed significantly between suboptimal 
and constant statin user groups at V2, and examining the potential for healthy user bias by 
considering PPI prescription changes between baseline discharge and V2.   
 
The expanded statin non-adherence definition was: patients that missed at least one statin 
pill (BMQ Qu. 1e), took a statin for six or fewer days (Qu. 1b) (both from regimen screen), 
reported that the statin did not work well for them or they did not know (Qu. 1g), found that 
the statin bothered them at least a little (Qu. 2) (both from belief screen) and those that 
found it at least somewhat hard to remember to take all of their pills (Qu. 3c the recall 
screen).   
 
All analyses were performed using IBM SPSS version 22.0 (IBM Corp, Armonk, NY, 
USA).  
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Results 
Figure 1 outlines the cohort selection process for this study.  1,005 patients discharged on a 
high potency statin were included; >99% were prescribed atorvastatin 80mg daily. 156 
patients (15.5%) were suboptimal statin users by V2; 849 (84.5%) remained on and adherent 
to high potency statin therapy, constituting constant statin users.   
 
Of 1005 eligible patients discharged from hospital with a diagnosis of non-ST elevation 
acute coronary syndrome on recommended high potency statin therapy, 156 (15.5%) had 
inadequate statin utilisation by a median of one month following hospital discharge; 849 
(84.5%) patients remained on and adherent to high potency statin therapy at V2. 
 
Factors associated with suboptimal statin occurrence 
Suboptimal and constant statin users were broadly similar (Table 1).  However, in 
multivariable logistic regression, being female (p=0.010), not on either a P2Y12 inhibitor 
(p=0.007) or beta blocker at V2 (p=0.036), and being bothered by muscular symptoms 
(p=0.017) were all associated with an increased adjusted risk of suboptimal statin occurrence 
(Table 2).   
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Table 1 Characteristics of suboptimal and constant statin users  
Variable Suboptimal 
Statin therapy 
Constant Statin 
users 
Unadjusted p-
value 
Patients (%) 156 (15.6) 
 
849 (84.4) 
 
 
Median follow up from V2 
(months) 
16 
 
15 0.52 
 
Demographics 
Age ≥ 75, n (%) 39 (25.0) 161 (19.0) 0.13 
Men, n (%) 102 (65.4) 660 (77.4) 0.004 
BMI ≥ 30, n (%) 54 (34.6) 292 (33.4) 0.92 
Medical History, n (%) 
Hypertension 93 (59.6) 490 (57.7) 0.63 
Hyperlipidaemia 75 (48.1) 455 (53.6) 0.27 
Diabetes mellitus 43 (27.6) 43 (27.6) 0.091 
Ever smoked  113 (72.4) 588 (69.3) 0.42 
CKD (Cr>150µmol/L) 13 (8.3) 48 (5.7) 0.28 
COPD 13 (8.3) 74 (8.7) 0.89 
Prior CVD1 51 (32.7) 287 (33.8) 0.82 
On Statin prior to index 
admission 
79 (50.6) 387 (45.6) 0.30 
Diagnosis, n (%)2 
Troponin-raised NSTE-ACS  149 (95.5) 828 (97.5) 0.16 
Normal troponin NSTE-ACS 7 (4.5) 21 (2.5) - 
Treatment, n (%) 
PCI/CABG 72 (46.2) 401 (47.2) 0.80 
Discharged on Atorvastatin 
80mg daily 
155 (99.4) 843 (99.3) 0.91 
NYHA Functional Classification at Visit 2, n (%) 
Class I 82 (52.6) 457 (53.8) 0.61 
Class II 56 (35.9) 314 (37.0)  
Class III 18 (11.5) 70 (8.3)  
Class IV 0 (0.0) 8 (0.9)  
Drugs at Visit 2, n (%) 
Aspirin 142 (91.0) 795 (93.6) 0.36 
P2Y12 inhibitor 122 (78.2) 738 (86.9) 0.006 
Beta blocker 119 (76.3) 725 (85.4) 0.016 
ACEI/ARB 121 (77.6) 706 (83.2) 0.11 
Warfarin 6 (3.9) 41 (4.8) 0.57 
Proton pump inhibitor 67 (43.0) 358 (42.2) 0.89 
CYP3A4-inhibitors 19 (12.2) 66 (7.8) 0.080 
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Levothyroxine 6 (3.8) 39 (4.6) 0.67 
Muscular symptoms at V2, n 
(%) 
5 (3.2) 7 (0.8) 0.020 
ACEI = angiotensin converting enzyme inhibitor; ARA = aldosterone receptor antagonist; ARB = angiotensin 
II receptor blocker; BMI = body mass index; CABG = coronary artery bypass graft surgery; CKD = chronic 
kidney disease; COPD = chronic obstructive pulmonary disease; Cr = creatinine; CVD = cardiovascular 
disease; CYP3A4 = cytochrome P450 3A4 drug-metabolising enzyme; LD = loop diuretic; NSTE-ACS = non-
ST elevation acute coronary syndrome; PCI = percutaneous coronary intervention; V2 = Visit two. 
1 
= Prior CVD encompasses past MI, stroke, TIA or PAD; 2 = raised troponin taken to indicate non-ST 
elevation myocardial infarction (NSTEMI), and a normal troponin unstable angina.   
 
Table 2 Adjusted factors associated with suboptimal statin occurrence  
Risk factor Suboptimal 
Statin therapy, 
n (%) 
Constant 
Statin users, 
n (%) 
Multivariable analysis 
OR (95% CI) p-value 
Muscular symptoms 5 (3.2) 7 (0.8) 4.28 (1.30-14.08) 0.017 
Sex (F vs M) M: 102 (65.4) M: 660 (77.4) 1.75 (1.14-2.68) 0.010 
P2Y12 inhibitor at V2  122 (78.2) 738 (86.9) 0.53 (0.34-0.84) 0.007 
Beta blocker at V2 119 (76.3) 725 (85.4) 0.59 (0.36-0.96) 0.036 
Covariates with univariate p<0.1 were entered into multivariable logistic regression modelling using a 
forwards likelihood ratio method to select the multivariable model presented here.  
 
Risks of MACE and ACM associated with suboptimal statin use 
The median study duration after V2 was 16 months, and there were 113 MACE and 79 
ACM events; 33% of ACM deaths were non-cardiovascular.  Table 3 shows the results of 
the univariate analyses of association between time to MACE, or time to ACM, and each 
variable considered.  Of patients with suboptimal statin use, 32 and 25 suffered MACE and 
ACM, respectively.  In multivariable analysis, suboptimal statin use was a risk for both time 
to MACE (HR 2.10, 95% confidence interval (CI) 1.25-3.53, p=0.005) and time to ACM 
(HR 2.46, 95% CI 1.38-4.39, p=0.003), after adjusting for age≥ 75, prior CVD, PCI/CABG 
treatment, NYHA class, and either diabetes mellitus (time to MACE) or chronic kidney 
disease (time to ACM) (Table 4). The adjusted survival curves, stratified by suboptimal 
statin status, are illustrated in Figures 2A and 2B, and demonstrate early separation of 
hazard risk after V2.   
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Table 3 Univariate Cox regression analysis results for association with time to MACE or 
time to ACM. 
Variable Time to MACE (n=113) Time to ACM (n=79) 
HR (95% CI) p-value HR (95% CI) p-value 
Demographics 
Age ≥ 75 3.02 (2.07-4.40) <0.001 5.17 (3.31-8.07) <0.001 
Sex (F vs M) 1.31 (0.87-1.97) NS (p=0.19) * * 
BMI ≥  30 1.30 (0.89-1.90) NS (p=0.18) 1.40 (0.89-2.20) NS (p=0.14) 
Medical History 
Hypertension 1.82 (1.21-2.71) 0.004 2.12 (1.29-3.49) 0.003 
Hyperlipidaemia 1.56 (1.06-2.27) 0.023 1.90 (1.20-3.02) 0.007 
Diabetes mellitus 2.56 (1.76-3.74) <0.001 2.77 (1.78-4.33) <0.001 
Ever smoked 1.22 (0.80-1.86) NS (p=0.35) 1.33 (0.80-2.21) NS (p=0.27) 
CKD (Cr>150) 2.72 (1.65-4.47) <0.001 3.93 (2.34-6.61) <0.001 
COPD 1.39 (0.79-2.43) 0.26 1.88 (1.03-3.42) 0.039 
Prior CVD 3.06 (2.09-4.48) <0.001 4.25 (2.64-6.87) <0.001 
On statin prior to 
index admission 
1.66 (1.14-2.42) 
 
0.009 
 
2.01 (1.26-3.21) 
 
0.003 
 
Diagnosis 
Raised vs normal 
troponin NSTE-
ACS 
0.84 (0.34-2.09) 
 
NS (p=0.71) 
 
1.47 (0.36-6.01) 
 
NS (p=0.59) 
 
Treatment 
PCI/CABG  0.42 (0.28-0.63) <0.001 0.31 (0.18-0.53) <0.001 
Functional statin at V2 
NYHA 1.89 (1.51-2.37) <0.001 2.07 (1.60-2.70) <0.001 
Drugs at V2 
Suboptimal 
Statin therapy 
2.18 (1.40-3.40) 
 
0.001 2.54 (1.56-4.14) 
 
<0.001 
Aspirin 0.49 (0.28-0.86) 
 
0.013 
 
0.23 (0.13-0.38) 
 
<0.001 
 
P2Y12 inhibitor * * 0.66 (0.39-1.12) NS (p=0.12) 
Beta blocker 0.86 (0.53-1.42) 
 
NS (p=0.56) 0.76 (0.43-1.34) 
 
NS (p=0.34) 
ACEI/ARB 1.46 (0.84-2.55) NS (p=0.18) 1.16 (0.63-2.13) NS (p=0.63) 
Warfarin 2.23 (1.13-4.42) 0.022 2.94 (1.41-6.13) 0.004 
Proton pump 
inhibitor 
0.97 (0.67-1.42) 
 
NS (p=0.89) 1.40 (0.90-2.18) NS (p=0.14) 
* = Visit two P2Y12 status did not meet the proportional hazards assumption for MACE, and patient sex did not 
meet the proportional hazards assumption for ACM; these variables were considered in sensitivity analyses 
(see eTables 5, 8, 9 in the Supplement).  
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Table 4 Multivariable adjusted Cox regression results for risk of time to MACE or ACM 
Variable Time to MACE Time to ACM 
HR (95% CI) p-value HR (95% CI) p-value 
Suboptimal Statin therapy 2.10 (1.25-3.53) 0.005 2.46 (1.38-4.39) 0.003 
Age ≥ 75 2.05 (1.36-3.09) 0.001 3.47 (2.12-5.68) <0.001 
NYHA 1.48 (1.12-1.96) 0.006 1.62 (1.16-2.27) 0.005 
Treatment with PCI/CABG  0.56 (0.37-0.86) 0.008 0.49 (0.28-0.85) 0.011 
Prior CVD 2.00 (1.31-3.04) 0.001 2.43 (1.45-4.08) 0.001 
Diabetes mellitus 1.52 (1.002-2.30) 0.049 - - 
Chronic kidney disease - - 1.65 (0.93-2.93) 0.089 
Covariates with p<0.1 in univariate Cox analysis were entered into multivariable Cox regression modelling 
using the forwards likelihood ratio method to select the covariate model (variables not in bold font).  After 
these time to MACE or ACM covariate models were selected, the suboptimal statin therapy variable was 
entered into both models to produce the presented results. 
 
Sub-group analyses 
The subgroup of suboptimal statin users that had discontinued/were non-adherent (n=95) 
had significantly increased risks of MACE (HR 2.74 (1.49-5.04, p=0.001) and ACM (HR 
3.50 (1.69-7.23, p=0.001), compared to constant statin users (Table 5). The smaller 
subgroup of patients with reduced statin dose/switched statin (n=61), did not have 
significantly increased risks of MACE (p=0.24) or ACM (p=0.22) (Table 5). 
 
Sensitivity Analyses   Complete cases subcohort sensitivity analyses reinforce that muscular 
symptoms, female sex and beta blocker use were associated with suboptimal statin 
occurrence (eTables 2, 3 in the Supplement).  Suboptimal statin use was robustly associated 
with risks of MACE, and ACM, irrespective of adherence definition (Table 5), missing data 
imputation (Table 5, and eTable 5 in the Supplement), variables that did not meet the 
proportional hazards assumption (P2Y12 use for MACE and sex for ACM) and after 
inclusion of all variables associated with suboptimal statin occurrence (eTables 5-9 in the 
Supplement).  There was no substantive healthy user effect (eTables 5, 10, 11 in the 
Supplement).   
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Table 5 Summary of main results for the adjusted risks of time to MACE or ACM 
associated with suboptimal statin use 
Analysis Statin use, n (%) Time to MACE Time to ACM 
Suboptimal Constant HR (95% CI) p-
value 
HR (95% CI) p-
value 
Main Analysis 156 (15.5) 849 (84.5) 2.10 (1.25-3.53)1 
 
0.005 2.46 (1.38-4.39)2 
 
0.003 
Subgroup analyses: 
Statin discontinuation/ 
non-adherence only 
95 (10.1) 849 (89.9) 2.74 (1.49-5.04)3 0.001 3.50 (1.69-7.23)4 0.001 
Statin dose reduction/ 
switch only 
61 (6.7) 849 (93.3) 
 
1.55 (0.75-3.20)5 0.24 1.71 (0.72-4.04)6 0.22 
Main Sensitivity analyses: 
Including expanded non-
adherence definition  
272 (27.1) 733 (72.9) 1.75 (1.17-2.63)7 0.007 1.75 (1.06-2.89)8 0.030 
Complete cases analysis  89 (12.3) 635 (87.7) 2.60 (1.58-4.28)9 <0.001 3.41 (1.91-6.06)10 <0.001 
For each analysis (main, subgroup and sensitivity analyses for both time to MACE and time to ACM), a 
multivariable covariate model was fitted before the suboptimal statin variable was added.  Covariates with 
univariate p<0.1 were entered into multivariable Cox proportional hazards modelling, with the final 
multivariable covariate model for each analysis chosen by forwards stepwise (likelihood ratio) selection.  All 
analyses selected to adjust for age ≥ 75, prior cardiovascular disease (previous myocardial infarction, stroke, 
transient ischaemic attack or peripheral artery disease), New York Heart Association functional class at Visit 2 
and treatment with percutaneous coronary intervention or coronary artery bypass grafting surgery during 
baseline admission or within 30 days of discharge.  Other covariates adjusted for in specific analyses were: 
diabetes mellitus (analyses 1, 6, 7, 9, 10); chronic kidney disease (analyses 2, 3, 4, 8). 
 
Discussion   
The main findings of this study are firstly, by a median of one month after admission for 
NSTE-ACS in patients discharged on high potency statin therapy, ~15% have suboptimal 
statin utilisation.  Expanding the non-adherence definition increased this to 27% (Table 5).  
Secondly, suboptimal statin occurrence was associated with muscular symptoms, female 
sex, and reduced use of beta blockers and P2Y12 inhibitors.  Thirdly, suboptimal statin use 
was associated with increased adjusted risks of times to both MACE and ACM, although 
this was largely attributable to statin discontinuation/non-adherence early after NSTE-ACS 
rather than statin dose reduction/statin switching.   
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This study is novel because it considered all components of attenuated statin therapy 
(discontinuation, non-adherence, switching and dose reduction), both collectively and in 
subgroups.  To date, the majority of adherence studies have assessed medication availability 
(e.g. proportion of days covered) via electronic data sources23-25.  Although this approach 
allows assessment of average adherence over time, it is difficult for healthcare professionals 
to easily measure and act upon in practice.  Importantly, the pragmatic approach used in this 
study highlights the importance of assessing statin usage early after hospital discharge in 
CVD secondary prevention patients.  Furthermore, the assessment of statin utilisation used 
in this study is relatively straightforward and so is potentially actionable.   
 
Overall, there were few differences at V2 between suboptimal and constant statin users.  
However interestingly, females23, 24, 26, 27 and a lower rate of beta blocker23, 28 and 
antiplatelet29 drug use have all previously been associated with poorer statin adherence.  In 
this study, suboptimal statin users were more likely to have not been prescribed P2Y12 
therapy at hospital discharge and to have stopped the beta blocker they were discharged on 
(data not shown).  This study also found that muscular symptoms were a risk factor for 
suboptimal statin use.  Very few other statin utilisation studies have included potential 
adverse events, although a cross-sectional internet-based survey previously determined that 
muscular symptoms are reported more frequently in patients that have discontinued, 
switched statin or are non-adherent, compared to non-switching statin adherent 
participants27.  Overall, there was no evidence that these differences altered the 
multivariable increased risks of time to MACE or ACM associated with suboptimal statin 
use (eTables 8 and 9 in the Supplement).   
 
Statins are associated with increased myotoxicity, incident diabetes mellitus and probably 
haemorrhagic stroke30.  Statin-associated muscular symptoms are reported in ~1.5-3% of 
statin users in RCTs31 and in ~7-29% of patients in observational studies32.  However, whilst 
rare statin-induced severe myopathy/rhabdomyolysis is incontrovertible, the contribution of 
statins to milder muscle symptoms remains controversial.  One informative estimate for the 
extent of muscular symptoms attributable to statin therapy is ~5%33, which is derived from a 
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blinded RCT that compared rates of stringently defined myalgia in healthy volunteers 
receiving either atorvastatin 80mg daily or placebo for six months (p=0.05)33.  The reported 
rate of bothersome muscular symptoms in our observational study was low (~1.2%) (Table 
1).  This may be a reflection of muscular symptoms not being explicitly asked about, and/or 
because patients who experienced muscular symptoms shortly after discharge had amended 
their statin therapy by V2, with potential symptomatic resolution.  There is currently no 
unifying mechanistic explanation for statin-induced myotoxicity.  However, several factors 
increase risk including female sex, advanced age, hypothyroidism, chronic kidney disease, 
exercise, drug-drug interactions, and for simvastatin myopathy specifically a genetic variant 
(SCLO1B1 rs4149056) is a risk factor34.     
 
The largest type of suboptimal statin users in this study was statin non-adherent patients.  
The aetiology of statin non-adherence is multifactorial and incompletely understood; 
predictors beyond those identified in this study include age, low income and increased non-
cardiovascular medications35.  Health beliefs and knowledge affect both perceptions of need 
for a treatment, and counteracting perceptions of potential treatment adverse effects, are 
influenced by factors such as patient satisfaction with physician treatment explanations, and 
likely also modulate non-adherence36.  Therefore, irrespective of the exact underlying 
aetiology of mild muscular symptoms, the attribution of these symptoms to statin therapy by 
a patient will potentially reduce statin utilisation.   
 
Another potential reason for the statin discontinuation/dose reductions/statin switching 
observed in this study early after an NSTE-ACS is a communication breakdown leading to 
the high potency statin hospital discharge prescription not being transferred and incorporated 
into a patient’s repeat outpatient prescription drug list.  Transfer of medical information 
from secondary to primary care is often incomplete and untimely37, 38, although further 
research is required to evaluate the extent of its potential impact on early post-ACS 
suboptimal statin therapy.   
 
Previous secondary prevention cohorts have reported elevated risk estimates for statin non-
adherence or discontinuation/persistence of 1.01-5.26 for MACE and 1.25-5.00 for 
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mortality, with the majority reporting statistically significant results39.  Our study results of 
increased adjusted risks of time to MACE or ACM associated with both suboptimal statin 
use and the statin non-adherence/discontinuation subgroup in particular are in keeping with 
these findings.  This emphasises the generalizability of these clinically relevant findings 
across secondary prevention populations, settings and study designs.   
 
In this study of NSTE-ACS patients, the statin dose reduction/switching statin subgroup was 
not significantly associated with increased risks of time to MACE or ACM.  One other 
prospective study has investigated statin dose reduction/switching following ACS, but 
included both NSTE-ACS and ST-elevation ACS patients, and reported a significantly 
increased risk for adverse clinical outcomes (HR 2.7, 95% CI 1.7-5.1)14.  Our smaller 
number of dose reduction/switching cases (n=61) may have accounted for this subgroup 
only showing a non-significant trend for increased risk.  Two other observational studies 
have investigated the influence of switching from atorvastatin to simvastatin40, 41 on 
cardiovascular events, using mixed primary/secondary prevention populations identified 
using electronic healthcare databases.  The UK-based study found a modestly increased 
cardiovascular event risk (HR 1.30, 95% CI 1.02-1.64)40, whilst the US-based study found 
no association41.  However in both of these studies the majority of patients were on 
atorvastatin ≤20mg/day, and it has been noted that the proportion of switches from 
atorvastatin to a lower rather than equivalently potent simvastatin regimen increases as the 
initial atorvastatin dose increases41.  This is particularly relevant in post-ACS patients, as 
practically all switches from atorvastatin 80mg/day are to another statin of lower equivalent 
potency.  Overall, persistent adherence to high potency statin therapy after an ACS appears 
optimal; however, if necessary, reducing the dose or switching statin appears preferable to 
statin non-adherence or complete discontinuation.  
 
Recently, several interventions have been proposed that attempt to reduce non-
adherence/discontinuation and improve statin therapeutic effectiveness, including improving 
CVD and statin literacy, co-payment reduction, using fixed-dose ‘polypill’ combinations 
and behaviour-modification interventions17.  For example, brief pharmacist-led face-to-face 
counselling sessions have been shown to improve statin adherence42.  There is also 
increasing interest in utilising mobile technology applications (apps) to remind patients to 
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take their medications, and patients are being involved in medication-related app 
development43.  It is thus plausible that an intervention based on reminders (e.g. apps and/or 
posted letters) and face-to-face contact could be targeted to patients early after a CVD event 
to both screen for and address suboptimal statin utilisation, although further research is 
required. 
 
Our study has limitations.  It is a post hoc assessment of the PhACS study.  The exact 
reasons for statin prescription changes and the cause(s) for patient non-adherence were not 
recorded.   The data are observational and therefore we cannot confirm causality due to the 
potential for confounding influences by unmeasured variables, such as cardiac rehabilitation 
attendance.  Although we cannot definitively exclude any healthy user effect, our 
assessment of PPI utilisation (eTables 10 and 11 in the Supplement) is in keeping with the 
lack of healthy user effect reported in other statin utilisation studies23, 24, 44, and so makes a 
prominent contribution of this type of influence unlikely.  It is acknowledged that both the 
assessment of statin adherence at a single time point and basing the primary assessment on 
the number of pills missed over the preceding week will limit detection of sporadic non-
adherence22.  However, the expanded non-adherence definition (Table 5) includes all 
components of the BMQ and the BMQ recall screen (enquiring about how hard the patient 
finds it to remember to take all the pills) has a sensitivity of 90% for sporadic non-
adherence, albeit with a reduced specificity of 80%22.  The assessment of statin utilisation at 
one month is also unlikely long enough to capture full stabilisation of drug use.  However, 
median statin discontinuation in secondary prevention appears to occur at 30-37 days after 
discharge14, 45, and our approach does not preclude follow up adherence assessments.  
Overall, this investigation used a prospective multicentre study with event validation rather 
than electronic diagnostic codes, and the several sensitivity analyses confer robustness to the 
main findings.  
 
In conclusion, patients with an NSTE-ACS are at high risk of subsequent MACE and ACM.  
Following discharge on high potency statin therapy, the intensity of statin therapy is already 
reduced for a sizeable proportion of patients by one month back in the community, and self-
reported muscular symptoms appear to increase the risk for suboptimal statin utilisation.  
Early statin discontinuation/non-adherence correlates with increased risks of subsequent 
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MACE and ACM.  Physicians, pharmacists and cardiac rehabilitation programmes are 
encouraged to discuss statin therapy with ACS patients early after discharge, reaffirm the 
benefits of statins, and explore barriers to their effective use in order to maintain and 
enhance statin utilisation and so potentially improve post NSTE-ACS outcomes.  
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Figure legends 
Figure 1 A schematic of the study selection process. 
 
Figure 2 Cumulative survival curves  
The cumulative survival curves compared suboptimal statin (green) and constant statin use (blue) group 
survival free from; A) major adverse cardiovascular events (MACE) and; B) all-cause mortality (ACM).  
Survival curves plotted until last event occurrence. 
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Highlights 
 
• Deviation from high potency statin therapy is common early in secondary prevention 
• Deviation can be by discontinuation, dose reduction, switching or non-adherence  
• Muscular symptoms are associated with suboptimal statin use 
• Statin discontinuation/non-adherence is associated with increased adverse outcomes 
• Interventions to enhance statin use could improve secondary prevention outcomes 
